Impact of Covid-19 on Occupational Dermato-allergology Consultations of Health Peronnel
Impact of Covid-19 on Occupational Dermato-allergology Consultations of Health Peronnel
Occupational dermatitis is the second most common occupational disease in Europe, with a notable prevalence among healthcare workers-approximately 20% of whom are affected. However, these figures may be underestimated due to underreporting. Despite the presumed scale of the problem, there is no recent European data providing real numbers. This study seeks to address the knowledge gap regarding the impact of the COVID-19 pandemic on occupational dermatitis within the healthcare workers population.
EPIDERMAPS is a retrospective cohort study that analyzes data from two specialized centers in the Paris region. The primary goal is to assess changes in the proportion of dermatology-allergology consultations among healthcare workers before and after the COVID-19 pandemic. Secondary objectives include evaluating the pandemic's effect on occupational dermatoses incidences, attributed to increased PPE and hygiene products usage. The major focus will be on work-related allergic contact dermatitis, irritant contact dermatitis, contact urticaria, acne, and rosacea. The latter objective is to identify new allergens or contributing factors.
Participants include active healthcare workers aged 18 or older who sought consultations for dermatological or dermatology-allergology related motifs between March 15, 2017, and March 15, 2023. Exclusions apply for patients who have consulted for other than dermatology-allergology related motif and those opposing to participate. Data will be stored, anonymized, and analyzed using EasyMedStat. Data collection is scheduled between March and December 2024.
This research aims to offer insights into COVID-19's dermatologic and allergic effects on healthcare professionals, informing future preventive measures and enhanced care strategies.
Occupational dermatoses include several dermatological conditions, the most common are allergic contact dermatitis, irritant contact dermatitis, contact urticaria, acne, and rosacea. Occupational dermatitis is the second most common occupational disease in Europe, with a notable prevalence among healthcare workers-approximately 20% of whom are affected. However, these figures may be underestimated due to underreporting. Despite the presumed scale of the problem, there is no recent European data providing real numbers. This study seeks to address the knowledge gap regarding the impact of the COVID-19 pandemic on occupational dermatitis within the healthcare workers population.
EPIDERMAPS is a retrospective cohort study that analyzes data from two Parisian centers specialized in occupational dermatology and allergology - Centre Hospitalier Intercommunal de Créteil and l'Hôpital Hôtel Dieu in Paris. Both centers are recognized at the national level as the Occupational and Environmental Disease Consultation Center (Centre de Consultation de Pathologies Professionnelles et de l'Environnement).
The primary goal is to analyze the impact of the COVID-19 on the proportion of dermatology-allergology consultations of healthcare workers in relation to the total number of consultations in these two centers, before and after the pandemic.
Secondary objectives include:
The Inclusion criteria require to be an active healthcare worker aged 18 or older at the date of the first consultation. Further criteria are to have consulted for dermatological or dermatology-allergology related motifs between March 15, 2017, and March 15, 2023. Exclusions apply for non-healthcare workers, patients who have consulted for other than dermatology-allergology related motif, and those opposing to participate. Patient identification involves querying the National Network for Surveillance and Prevention of Occupational Diseases (RNV3P, Réseau National de Vigilance et de Prévention des Pathologies professionnelles). Eligible patients will be informed by mail, and if no opposition expressed, their data will be collected and stored anonymously for analysis. Patient data will be collected from medical records, anonymized, and stored securely. Data collection is programmed from March to December 2024. The study comprises 471 patients from two centers.
The collected data will include:
Age at the first consultation
Date of the first consultation
Date of birth (month and year)
Gender
Occupation
Duration in the profession
Diagnosed condition(s)
Date of symptom onset
Nature of symptoms
Location of lesions
Identified aggravating/triggering factors
Professional rhythm of lesions
History, such as:
Patch test results and their relevance
Prick test results
Socio-professional outcome (job accommodation, job change, career reorientation, etc.)
Statistical analyses will use EasyMedStat to respond to the primary and secondary objectives.
The study has been officially approved by the Local Ethics Committee (CEL) of Créteil on the December 19th, 2023.
In conclusion, this research aims to provide new data on COVID-19's dermatologic and allergic effects on healthcare professionals, informing future preventive measures and enhanced care strategies.
Inclusion Criteria:
Exclusion Criteria: